NASDAQ:CTIC - CTI BioPharma Stock Price, Forecast & News

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

CTI BioPharma's stock reverse split before market open on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma stock prior to the reverse split would have 10 shares after the split.

CTI BioPharma Corp (NASDAQ:CTIC) released its quarterly earnings results on Monday, November, 4th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.23) by $0.06. The biopharmaceutical company had revenue of $2.29 million for the quarter. CTI BioPharma had a negative net margin of 177.54% and a negative return on equity of 78.10%. View CTI BioPharma's Earnings History.

CTI BioPharma is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for CTI BioPharma.

2 equities research analysts have issued 1 year price objectives for CTI BioPharma's shares. Their forecasts range from $4.00 to $4.00. On average, they expect CTI BioPharma's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 198.5% from the stock's current price. View Analyst Price Targets for CTI BioPharma.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CTI BioPharma.

News stories about CTIC stock have been trending very negative on Wednesday, according to InfoTrie. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CTI BioPharma earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for CTI BioPharma.

CTI BioPharma saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 290,500 shares, an increase of 26.4% from the December 15th total of 229,800 shares. Based on an average daily trading volume, of 408,200 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.5% of the shares of the stock are short sold. View CTI BioPharma's Current Options Chain.

Some companies that are related to CTI BioPharma include Neptune Wellness Solutions (NEPT), MediciNova (MNOV), Osmotica Pharmaceuticals (OSMT), Avadel Pharmaceuticals (AVDL), BioXcel Therapeutics (BTAI), VBI Vaccines (VBIV), Geron (GERN), IVERIC bio (ISEE), Evofem Biosciences (EVFM), Wave Life Sciences (WVE), Sol Gel Technologies (SLGL), Hookipa Pharma (HOOK), Kamada (KMDA), MEI Pharma (MEIP) and BIOFRONTERA AG/ADR (BFRA).

Based on aggregate information from My MarketBeat watchlists, some companies that other CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Banco Santander Brasil (BSBR), Freeport-McMoRan (FCX), PETROLEO BRASIL/ADR (PBR), Reshape Lifesciences (RSLS) and La Jolla Pharmaceutical (LJPC).

Shares of CTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CTIC stock can currently be purchased for approximately $1.34.

CTI BioPharma has a market capitalization of $77.69 million and generates $26.29 million in revenue each year. CTI BioPharma employs 46 workers across the globe.View Additional Information About CTI BioPharma.

The official website for CTI BioPharma is http://www.ctibiopharma.com/.

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The biopharmaceutical company can be reached via phone at 206-282-7100 or via email at [email protected]